Literature DB >> 18506458

Tumor markers in mature cystic teratomas of the ovary.

Emin Ustunyurt, Ustunyurt Emin1, Tayfun Gungor, Gungor Tayfun, Cantekin Iskender, Iskender Cantekin, Basak Ozlem Ustunyurt, Ustunyurt Basak Ozlem, Umit Bilge, Bilge Umit, Leyla Mollamahmutoglu, Mollamahmutoglu Leyla.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the serum levels of tumor markers in patients with ovarian mature cystic teratomas.
METHOD: Retrospective study of 215 patients operated at Zekai Tahir Burak Women Health Education and Research Hospital between January 2001 and October 2006 was performed.
RESULTS: The median age was 36 years (range 13-80). The mean tumor diameter was 7.7 +/- 4.6 cm (range 2-25). The mean serum CA 125 level was 26.2 +/- 29.9 U/mL (range 1.4-225, normal value <35), and the mean serum CA 19-9 level was 83.5 +/- 179.2 IU/mL (range 0.6-1,000; normal value <37). The elevated rate of CA 19-9, CA 125 was 39.6% (74/187) and 23.3% (50/215), respectively. The mean age of patients and the rate of bilaterality of tumors were similar in both patients with elevated CA19-9 and with normal CA 19-9 level (P > 0.05). The mean tumor size of patients with elevated CA 19-9 was greater than those with normal CA19-9 level (P = 0.01).
CONCLUSION: Serum CA 19-9 has the highest positivity rate among other tumor markers in ovarian mature cystic teratomas. Elevated serum CA 19-9 levels are correlated with larger tumor size. But the diagnostic value of elevated CA 19-9 in patients with MCT would be poor if the test was used alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506458     DOI: 10.1007/s00404-008-0688-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  15 in total

1.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

2.  MicroRNA expression profiling of mature ovarian teratomas.

Authors:  Ye Ding; Xiao-Yan Gu; Feng Xu; Xiao-Yan Shi; DA-Zheng Yang; Jian Zhong; Su-Min Wang
Journal:  Oncol Lett       Date:  2011-10-12       Impact factor: 2.967

3.  Current diagnostic approach to patients with adnexal masses: which tools are relevant in routine praxis?

Authors:  Milan M Terzic; Jelena Dotlic; Ivana Likic; Nebojsa Ladjevic; Natasa Brndusic; Nebojsa Arsenovic; Sanja Maricic; Tihomir Mihailovic; Sasa Andrijasevic
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

4.  An uncommon recurrence of an immature teratoma: A case report.

Authors:  Xuelu Li; Dandan Zhu; L I Lv; Jian Yu
Journal:  Oncol Lett       Date:  2016-02-19       Impact factor: 2.967

5.  Significant simultaneous changes in serum CA19-9 and CA125 due to prolonged torsion of mature cystic teratoma of the ovary.

Authors:  Dong Soo Suh; Soo Hyun Moon; Seung Cheol Kim; Jong Kil Joo; Won Young Park; Ki Hyung Kim
Journal:  World J Surg Oncol       Date:  2014-11-22       Impact factor: 2.754

6.  Correlation of CA-125 serum level and clinico-pathological characteristic of patients with endometriosis.

Authors:  Mojgan Karimi-Zarchi; Najmeh Dehshiri-Zadeh; Leili Sekhavat; Fahime Nosouhi
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-11

7.  Abnormal Elevated CA 19-9 in the Dermoid Cyst: A Sign of the Ovarian Torsion?

Authors:  Burcu Artunc Ulkumen; Asli Goker; Halil Gursoy Pala; Sercin Ordu
Journal:  Case Rep Obstet Gynecol       Date:  2013-06-11

8.  CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma.

Authors:  Hye-yon Cho; Kidong Kim; Yong-Tark Jeon; Yong-Beom Kim; Jae Hong No
Journal:  Med Sci Monit       Date:  2013-03-29

9.  A case of recurrent, bilateral ovarian mature teratoma in a young woman.

Authors:  Che-Fu Chang; Chen-Kuo Lin
Journal:  BMC Womens Health       Date:  2014-04-13       Impact factor: 2.809

10.  Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.

Authors:  Hye-Yon Cho; Min Sun Kyung
Journal:  Med Sci Monit       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.